Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Multiomics dissection of molecular regulatory mechanisms underlying autoimmune-associated noncoding SNPs
Xiao-Feng Chen, … , Yan Guo, Tie-Lin Yang
Xiao-Feng Chen, … , Yan Guo, Tie-Lin Yang
Published September 3, 2020
Citation Information: JCI Insight. 2020;5(17):e136477. https://doi.org/10.1172/jci.insight.136477.
View: Text | PDF
Research Article Genetics

Multiomics dissection of molecular regulatory mechanisms underlying autoimmune-associated noncoding SNPs

  • Text
  • PDF
Abstract

More than 90% of autoimmune-associated variants are located in noncoding regions, leading to challenges in deciphering the underlying causal roles of functional variants and genes and biological mechanisms. Therefore, to reduce the gap between traditional genetic findings and mechanistic understanding of disease etiologies and clinical drug development, it is important to translate systematically the regulatory mechanisms underlying noncoding variants. Here, we prioritized functional noncoding SNPs with regulatory gene targets associated with 19 autoimmune diseases by incorporating hundreds of immune cell–specific multiomics data. The prioritized SNPs are associated with transcription factor (TF) binding, histone modification, or chromatin accessibility, indicating their allele-specific regulatory roles. Their target genes are significantly enriched in immunologically related pathways and other known immunologically related functions. We found that 90.1% of target genes are regulated by distal SNPs involving several TFs (e.g., the DNA-binding protein CCCTC-binding factor [CTCF]), suggesting the importance of long-range chromatin interaction in autoimmune diseases. Moreover, we predicted potential drug targets for autoimmune diseases, including 2 genes (NFKB1 and SH2B3) with known drug indications on other diseases, highlighting their potential drug repurposing opportunities. Taken together, these findings may provide useful information for future experimental follow-up and drug applications on autoimmune diseases.

Authors

Xiao-Feng Chen, Ming-Rui Guo, Yuan-Yuan Duan, Feng Jiang, Hao Wu, Shan-Shan Dong, Xiao-Rong Zhou, Hlaing Nwe Thynn, Cong-Cong Liu, Lin Zhang, Yan Guo, Tie-Lin Yang

×

Figure 3

Allele-specific epigenetic effect mediated by risk alleles of prioritized SNPs.

Options: View larger image (or click on image) Download as PowerPoint
Allele-specific epigenetic effect mediated by risk alleles of prioritize...
(A) Risk allele of rs4482069 is associated with higher histone modification (H3K4me3) in lymphoblastoid cell lines (LCLs), which may facilitate allele-specific binding of KLF1 and activate the enhancer activity to increase SLC15A4 expression. (B) Risk allele of rs3784789 is associated with lower chromatin accessibility in LCLs, which may hamper binding of several TFs (SPIC, ETV6, and ELF1) and restrain the enhancer activity to decrease CSK expression. (C and D) Motif prediction revealed that CTCF had allele-specific binding to the nonrisk allele of rs2234059 (C) and risk allele of rs2799079 (D), respectively. The higher or lower CTCF binding may result in weaker (C) or stronger (D) long-range loop formation between SNP and target gene promoter, and further decrease (C) or increase (D) target gene expression, respectively. Detailed results for A–D appear in Supplemental Table 5 and Supplemental Table 7. More allele-specific regulatory examples are summarized in Supplemental Table 9.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts